Advertisement
HomeCollectionsCervical Cancer
IN THE NEWS

Cervical Cancer

NEWS
January 11, 2010
The number of cervical cancer cases diagnosed annually has gone down markedly over the past 30 years, a drop attributed to cervical cytology screening (the Pap smear). The American College of Obstetrics and Gynecology recently changed its guidelines for cervical cancer screening. Dr. Diane Boykin of St. Agnes Hospital discusses what you need to know about the new guidelines. The new guidelines state that all Pap smears can begin at age 21. This is a subtle change from the previous recommendation, which had screening begin by age 21 or one to three years after the onset of sexual activity.
Advertisement
BUSINESS
By Mark Guidera and Mark Guidera,SUN STAFF | June 6, 1999
At health clinics operated by Omnia Inc. in Chicago and the Northeast, women are routinely tested for cervical cancer using that stalwart of gynecology, the Pap smear, and a new, more sensitive test that many medical experts believe could one day replace it.Philadelphia-based Omnia, which manages private gynecology practices serving 400,000 women, is the first managed care organization in the United States to use the new test in conjunction with the Pap....
BUSINESS
By Mara H. Gottfried and Mara H. Gottfried,CONTRIBUTING WRITER | January 15, 2000
Gaithersburg-based Digene Corp. said yesterday that it has come to an agreement with Laboratory Corporation of America Holdings to use its HPV test, which helps detect cervical cancer in women. Vandana K. Bapna, a biotechnology analyst at Hunt Valley-based Offutt Securities, called the deal significant for Digene, a biotechnology company that focuses on DNA and RNA technology for the detection, screening and monitoring of sexually transmitted diseases. "LabCorp is one of the largest reference testing labs in the United States," Bapna said.
BUSINESS
By Mark Guidera and Mark Guidera,SUN STAFF | May 12, 1999
Digene Corp. a Beltsville-based developer of DNA-based medical tests for diseases, said yesterday that drug giant Abbott Laboratories will act as the marketer and distributor for its tests in Europe, the Middle East and Africa.Among the tests Abbott will market are Digene's diagnostic products for hepatitis B and the human papillomavirus (HPV), considered a precursor to cervical cancer.In the United States, Abbott, one of the world's largest marketers of medical diagnostics, will launch sales of Digene's new automated tests for chlamydia, a urinary tract infection, and gonorrhea, a sexually transmitted disease.
HEALTH
By Meredith Cohn | January 27, 2012
The percentage of Americans screened for cancer isn't meeting national targets, and the numbers are even worse for minorities, according the first federal study looking at disparities among Asiand and Hispanic groups. The report by the Centers for Disease Control and Prevention and the National Cancer Institute showed breast cancer screening rates were 72.4 percent, below the 81 percent target set in a national health plan called Healthy People 2020.  It was 83 percent for cervical cancer, missing the 93p ercent mark, and colorectal screening was 58.6 percent, missing hte 70.5 percent target.
BUSINESS
By Andrea K. Walker and Andrea K. Walker,SUN STAFF | March 12, 2002
Digene Corp., a maker of medical diagnostic tests, expects the marketing potential of its DNA-based cervical cancer test to increase 10-fold if the U.S. Food and Drug Administration approves expanded use. The Gaithersburg-based company cleared a major hurdle Friday when an FDA advisory panel recommended that Digene's test, with conditions, be used in conjunction with the Pap smear as a primary detector of cervical cancer. The FDA generally follows the advice of its advisory panels, which are made up of outside experts.
BUSINESS
By Rona Kobell and Rona Kobell,SUN STAFF | May 4, 2000
Digene Corp., the Gaithersburg-based maker of medical test kits, announced yesterday that Kaiser Permanente will use its flagship product to screen for cervical cancer. The 10-year-old company's Digital Hybrid Capture HPV test detects the human papillomavirus, a frequent precursor to cervical cancer. The HPV test is one of a handful of products Digene is developing, but it's the most successful so far, said Digene President Charles Fleischman. The test played prominently in Digene's earnings for the quarter ended March 31, which the company also released yesterday.
NEWS
January 14, 2007
Regular pelvic examinations urged Dr. Andrew Bernstein, health officer for Harford County, is urging women to have regular pelvic exams and pap tests to screen for cervical cancer. January is National Cervical Cancer Awareness Month. Women should also report any of the following symptoms to their physicians immediately: unusual discharge; blood spots or light bleeding other than a normal period; or bleeding or pain after sex, douching or a pelvic exam. The Health Department is sponsoring gynecological exams for women at no cost who meet program guidelines.
NEWS
By Donna E. Boller and Donna E. Boller,Staff Writer | April 6, 1993
Two Carroll County obstetrician-gynecologists are offering Carroll women what could be a chance at a longer life -- free Pap tests to detect possible cervical cancer.Dr. Melvin A. Yeshnik and his partner, Dr. Michael R. Barnett, will provide the tests from noon to 4 p.m. Friday, April 16, and 8 a.m. to noon Saturday, April 17, at their offices in Suite 306 of the Billingslea Medical Building, 542 Washington Road, Westminster.The American Cancer Society reports that approximately 13,000 women are diagnosed with cervical cancer each year and about 7,000 die from it. "In reality, no one in this country should die from cervical cancer" because Pap smears can provide early detection of abnormalities, Dr. Yeshnik said.
BUSINESS
By Julie Bell and Julie Bell,SUN STAFF | May 3, 2001
Digene Corp. said yesterday that strong U.S. sales of its cervical cancer tests drove quarterly revenue up 47 percent, but that costs from a scuttled secondary offering resulted in a loss equal to that of a year ago. The Gaithersburg company lost $1.6 million, or 10 cents per share, for its fiscal third quarter this year and last. The loss this year included about $500,000 - or 3 cents per share - in expenses related to an offering Digene pulled during the market slump in March. Analysts had predicted a loss of 9 cents per share, excluding the one-time costs, according to the average estimate of three analysts surveyed by Zacks Investment Research Inc. Quarterly revenue was $9 million, compared with $6.1 million a year ago. "It's pretty hard to be negative," said H. C. Wainright analyst Ronald Opel, who upgraded shares of Digene from an "accumulate" rating to a "buy" in March.
Baltimore Sun Articles
|
|
|
Please note the green-lined linked article text has been applied commercially without any involvement from our newsroom editors, reporters or any other editorial staff.